genscript biotech corp - GNNSF

GNNSF

Close Chg Chg %
4.00 0.60 15.00%

Closed Market

4.60

+0.60 (15.00%)

Volume: 5.10K

Last Updated:

Aug 25, 2026, 3:59 PM EDT

Company Overview: genscript biotech corp - GNNSF

GNNSF Key Data

Open

$4.15

Day Range

4.15 - 4.60

52 Week Range

1.30 - 4.60

Market Cap

$8.40B

Shares Outstanding

2.17B

Public Float

968.57M

Beta

0.84

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

$0.01

EX-DIVIDEND DATE

Jun 18, 2020

SHORT INTEREST

N/A

AVERAGE VOLUME

1.83K

 

GNNSF Performance

1 Week
 
3.63%
 
1 Month
 
100.00%
 
3 Months
 
128.57%
 
1 Year
 
187.77%
 
5 Years
 
N/A
 

GNNSF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About genscript biotech corp - GNNSF

Genscript Biotech Corp. operates as a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Life-science Services and Products, Biologics Development Services, and Industrial Synthetic Biology Products. The Life-science Services and Products segment provides research services and products used for life-science research and application. The Biologics Development Services segment focuses on services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and CGT products with an integrated platform. The Industrial Synthetic Biology Products segment comprises of industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Hong Kong.

GNNSF At a Glance

Genscript Biotech Corp.
40th Floor
Hong Kong,
Phone N/A Revenue 959.53M
Industry Biotechnology Net Income -532,830,000.00
Sector Health Technology 2025 Sales Growth 60.147%
Fiscal Year-end 12 / 2026 Employees 6,165
View SEC Filings

GNNSF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.604
Price to Book Ratio 0.871
Price to Cash Flow Ratio 10.28
Enterprise Value to EBITDA 9.808
Enterprise Value to Sales 3.366
Total Debt to Enterprise Value 0.189

GNNSF Efficiency

Revenue/Employee 155,640.876
Income Per Employee -86,428.224
Receivables Turnover 6.034
Total Asset Turnover 0.189

GNNSF Liquidity

Current Ratio 1.468
Quick Ratio 1.413
Cash Ratio 1.171

GNNSF Profitability

Gross Margin 57.654
Operating Margin 26.601
Pretax Margin -15.649
Net Margin -55.531
Return on Assets -10.518
Return on Equity -12.87
Return on Total Capital -11.663
Return on Invested Capital -12.543

GNNSF Capital Structure

Total Debt to Total Equity 15.385
Total Debt to Total Capital 13.334
Total Debt to Total Assets 12.551
Long-Term Debt to Equity 3.56
Long-Term Debt to Total Capital 3.085
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Genscript Biotech Corp - GNNSF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
625.70M 839.53M 599.15M 959.53M
Sales Growth
+22.43% +34.17% -28.63% +60.15%
Cost of Goods Sold (COGS) incl D&A
321.62M 429.98M 322.36M 406.32M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
64.16M 73.95M 61.54M 74.04M
Depreciation
58.74M 69.42M 59.31M 71.51M
Amortization of Intangibles
5.42M 4.53M 2.23M 2.53M
COGS Growth
+54.94% +33.69% -25.03% +26.05%
Gross Income
304.08M 409.55M 276.79M 553.20M
Gross Income Growth
+0.20% +34.68% -32.42% +99.86%
Gross Profit Margin
+48.60% +48.78% +46.20% +57.65%
2022 2023 2024 2025 5-year trend
SG&A Expense
738.16M 799.66M 262.84M 297.96M
Research & Development
390.10M 432.83M 53.79M 71.23M
Other SG&A
348.07M 366.83M 209.05M 226.73M
SGA Growth
+13.21% +8.33% -67.13% +13.36%
Other Operating Expense
- - - -
-
Unusual Expense
2.31M (29.23M) 171.69M 405.50M
EBIT after Unusual Expense
(436.39M) (360.88M) (157.74M) (150.25M)
Non Operating Income/Expense
17.99M 38.79M 38.71M 17.39M
Non-Operating Interest Income
13.22M 73.19M 28.89M 26.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
13.27M 27.51M 8.03M 17.29M
Interest Expense Growth
+457.99% +107.33% -70.80% +115.31%
Gross Interest Expense
13.27M 27.53M 8.48M 17.29M
Interest Capitalized
- - 15.00K 450.00K
-
Pretax Income
(431.66M) (349.60M) (127.06M) (150.16M)
Pretax Income Growth
+13.04% +19.01% +63.66% -18.18%
Pretax Margin
-68.99% -41.64% -21.21% -15.65%
Income Tax
(3.72M) 4.14M 7.64M 61.87M
Income Tax - Current - Domestic
5.78M 7.99M 18.06M 42.57M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(9.50M) (3.85M) (10.42M) 19.31M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(427.97M) (355.12M) (173.77M) (532.40M)
Minority Interest Expense
(201.12M) (259.64M) (106.59M) 426.00K
Net Income
(226.85M) (95.48M) (67.18M) (532.83M)
Net Income Growth
+34.79% +57.91% +29.63% -693.09%
Net Margin Growth
-36.26% -11.37% -11.21% -55.53%
Extraordinaries & Discontinued Operations
- - - (203.15M)
-
Discontinued Operations
- - - (203.15M)
-
Net Income After Extraordinaries
(226.85M) (95.48M) (270.33M) (532.83M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(226.85M) (95.48M) (270.33M) (532.83M)
EPS (Basic)
-0.1082 -0.0453 -0.1274 -0.2458
EPS (Basic) Growth
+36.84% +58.13% -181.24% -92.94%
Basic Shares Outstanding
2.10B 2.11B 2.12B 2.17B
EPS (Diluted)
-0.1082 -0.0453 -0.1274 -0.2458
EPS (Diluted) Growth
+36.84% +58.13% -181.24% -92.94%
Diluted Shares Outstanding
2.10B 2.11B 2.18B 2.17B
EBITDA
(369.92M) (316.16M) 75.49M 329.29M
EBITDA Growth
-22.99% +14.53% +123.88% +336.22%
EBITDA Margin
-59.12% -37.66% +12.60% +34.32%

Genscript Biotech Corp in the News